H. Soifer

发表

MicroRNAs in disease and potential therapeutic applications.

H. Soifer, J. Rossi, P. Saetrom, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

A role for the Dicer helicase domain in the processing of thermodynamically unstable hairpin RNAs

Pål Sætrom, John J. Rossi, Masayuki Sano, 2008, Nucleic acids research.

MicroRNAs in Disease and Potential Therapeutic Applications.

John J Rossi, Pål Sætrom, P. Sætrom, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells

H. Soifer, J. Rossi, Zhigang Wang, 2015, Nucleic acids research.

Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs.

H. Soifer, J. Rossi, M. Behlke, 2008, Oligonucleotides.

Silencing of gene expression by gymnotic delivery of antisense oligonucleotides.

H. Soifer, C. Stein, T. Koch, 2012, Methods in molecular biology.

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

P. Philip, A. Zhu, M. Borad, 2021, The lancet. Gastroenterology & hepatology.

Direct Regulation of Androgen Receptor Activity by Potent CYP17 Inhibitors in Prostate Cancer Cells*

H. Soifer, C. Stein, Naira E. Souleimanian, 2011, The Journal of Biological Chemistry.

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents

H. Soifer, C. Stein, L. Benimetskaya, 2009, Nucleic acids research.

A novel, helper-dependent, adenovirus-retrovirus hybrid vector: stable transduction by a two-stage mechanism.

H. Soifer, T. Shichinohe, K. Mitani, 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell‐free DNA results

M. Galsky, D. Bajorin, J. Rosenberg, 2020, Cancer.

Stable integration of transgenes delivered by a retrotransposon-adenovirus hybrid vector.

J. V. Moran, H. Soifer, H. Kazazian, 2001, Human gene therapy.

Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC

Anne Gatignol, John J. Rossi, Lars Aagaard, 2007, Nucleic acids research.

Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92‐Gene Assay

H. Soifer, M. Overman, G. Varadhachary, 2020, The oncologist.

Small interfering RNAs to the rescue: blocking L1 retrotransposition

H. Soifer, J. Rossi, 2006, Nature Structural &Molecular Biology.

Do Small RNAs Interfere With LINE-1?

H. Soifer, 2006, Journal of biomedicine & biotechnology.

A potential role for RNA interference in controlling the activity of the human LINE-1 retrotransposon

H. Soifer, J. Rossi, M. Behlke, 2005, Nucleic acids research.

Review Article Do Small Rnas Interfere with Line-1? Importance of Limiting L1 Retrotransposition in the Human Genome

H. Soifer, 2022 .

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

P. Wen, T. Cloughesy, N. Butowski, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

L1 retrotransposition in nondividing and primary human somatic cells.

J. V. Moran, H. Soifer, H. Kazazian, 2006, Proceedings of the National Academy of Sciences of the United States of America.

Antisense 2'-Deoxy, 2'-Fluoroarabino Nucleic Acid (2'F-ANA) Oligonucleotides: In Vitro Gymnotic Silencers of Gene Expression Whose Potency Is Enhanced by Fatty Acids.

H. Soifer, C. Stein, G. Deleavey, 2012, Molecular therapy. Nucleic acids.

siRNA target site secondary structure predictions using local stable substructures

H. Soifer, J. Rossi, Bret S. E. Heale, 2005, Nucleic acids research.

Antisense 2′-Deoxy, 2′-Fluoroarabino Nucleic Acid (2′F-ANA) Oligonucleotides: In Vitro Gymnotic Silencers of Gene Expression Whose Potency Is Enhanced by Fatty Acids

H. Soifer, C. Stein, G. Deleavey, 2012, Molecular therapy. Nucleic acids.

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

Hua Yu, Drew M. Pardoll, John J. Rossi, 2009, Nature Biotechnology.

TLR agonist–Stat3 siRNA conjugates: cell-specific gene silencing and enhanced antitumor immune responses

Hua Yu, R. Jove, A. Scuto, 2009, Nature biotechnology.

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity

Alan Ho, H. Soifer, V. Villaflor, 2023, bioRxiv.

Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma

Huamin Wang, H. Soifer, R. Wolff, 2016, BMC Cancer.

Retrotransposon-adenovirus hybrid vectors: efficient delivery and stable integration of transgenes via a two-stage mechanism.

H. Soifer, N. Kasahara, 2004, Current gene therapy.

Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.

M. Galsky, D. Bajorin, J. Rosenberg, 2019, Journal of Clinical Oncology.

Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs.

H. Soifer, J. Rossi, M. Behlke, 2008, Oligonucleotides.

Tipifarnib potentiates the antitumor effects of PI3K α inhibition in Tipifarnib potentiates the antitumor effects of PI3K inhibition in PIK3CA-and HRAS-dysregulated HNSCC via convergent inhibition PIK3CA-and HRAS-dysregulated HNSCC via convergent inhibition of mTOR activity of mTOR activity

H. Soifer, Zhiyong Wang, Hetika D. Vora, 2022 .